Published in Nat Genet on May 18, 2008
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res (2012) 2.49
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Regulation and function of DNA methylation in plants and animals. Cell Res (2011) 2.41
Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res (2009) 2.31
Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 2.28
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A (2009) 2.25
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood (2010) 2.11
Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res (2008) 2.08
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res (2012) 1.78
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Characterization of microRNAs involved in embryonic stem cell states. Stem Cells Dev (2010) 1.62
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
DNA methylation in mammals. Cold Spring Harb Perspect Biol (2014) 1.57
Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells. EMBO J (2009) 1.55
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res (2010) 1.53
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
DNA methylation reprogramming in cancer: does it act by re-configuring the binding landscape of Polycomb repressive complexes? Bioessays (2013) 1.45
Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet (2010) 1.44
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42
Genome-wide uH2A localization analysis highlights Bmi1-dependent deposition of the mark at repressed genes. PLoS Genet (2009) 1.36
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One (2010) 1.35
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell (2012) 1.34
Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res (2012) 1.32
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene (2011) 1.32
The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res (2009) 1.32
Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol (2010) 1.32
The H3K27me3 demethylase dUTX is a suppressor of Notch- and Rb-dependent tumors in Drosophila. Mol Cell Biol (2010) 1.32
EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res (2011) 1.30
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol (2011) 1.29
Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res (2009) 1.28
TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One (2010) 1.28
HHMD: the human histone modification database. Nucleic Acids Res (2009) 1.27
PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Mol Cell (2013) 1.27
DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. Cancer Res (2009) 1.26
The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One (2012) 1.25
Concepts of epigenetics in prostate cancer development. Br J Cancer (2008) 1.24
Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One (2011) 1.22
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest (2013) 1.21
Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res (2010) 1.20
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
The JARID2-PRC2 duality. Genes Dev (2010) 1.18
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther (2009) 1.16
Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J (2009) 1.15
Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol (2010) 1.14
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res (2013) 1.14
Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol (2011) 1.13
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res (2011) 1.13
Genomic insights into cancer-associated aberrant CpG island hypermethylation. Brief Funct Genomics (2013) 1.11
Update in lung cancer 2008. Am J Respir Crit Care Med (2009) 1.11
Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest (2011) 1.11
Cancer epigenetics: a brief review. ILAR J (2012) 1.09
Temporal uncoupling of the DNA methylome and transcriptional repression during embryogenesis. Genome Res (2011) 1.09
Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res (2013) 1.09
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet (2014) 1.09
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia (2008) 1.08
Epigenetic mediated transcriptional activation of WNT5A participates in arsenical-associated malignant transformation. Toxicol Appl Pharmacol (2008) 1.08
Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am (2010) 1.08
Histone H3.3 mutations: a variant path to cancer. Cancer Cell (2013) 1.07
Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS One (2010) 1.06
Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res (2010) 1.06
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics (2010) 1.05
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
Reactivation of L1 retrotransposon by benzo(a)pyrene involves complex genetic and epigenetic regulation. Epigenetics (2011) 1.03
Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol (2010) 1.02
Epigenetic regulation of EMT: the Snail story. Curr Pharm Des (2014) 1.02
To selectivity and beyond. Nat Biotechnol (2010) 1.02
SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters. Mol Cancer Res (2012) 1.01
Epigenetic regulation of miR-212 expression in lung cancer. PLoS One (2011) 1.01
Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells. PLoS One (2012) 1.01
Gene silencing induced by oxidative DNA base damage: association with local decrease of histone H4 acetylation in the promoter region. Nucleic Acids Res (2010) 1.00
A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer. BMC Syst Biol (2011) 0.99
Environmental studies of schizophrenia through the prism of epigenetics. Schizophr Bull (2008) 0.99
Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol (2012) 0.99
The role of epigenetics in the biology of multiple myeloma. Blood Cancer J (2014) 0.99
Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics (2013) 0.99
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res (2012) 0.99
Histone modifications and chromatin organization in prostate cancer. Epigenomics (2010) 0.99
Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol (2010) 0.98
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res (2004) 7.92
Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev (2002) 6.74
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
RNA polymerase II is required for RNAi-dependent heterochromatin assembly. Science (2005) 3.94
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol (2003) 2.73
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol (2003) 2.72
Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res (2002) 2.71
Epigenetics in cancer: what's the future? Oncology (Williston Park) (2011) 2.70
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res (2007) 2.59
Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell (2012) 2.53
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Season of conception in rural gambia affects DNA methylation at putative human metastable epialleles. PLoS Genet (2010) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
A chromodomain protein, Chp1, is required for the establishment of heterochromatin in fission yeast. EMBO J (2004) 2.45
Heterochromatin and RNAi are required to establish CENP-A chromatin at centromeres. Science (2008) 2.45
Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat Cell Biol (2005) 2.41
Gangliosides GM1 and GM3 in the living cell membrane form clusters susceptible to cholesterol depletion and chilling. Mol Biol Cell (2007) 2.38
Epigenetic changes in colorectal cancer. Cancer Metastasis Rev (2004) 2.35
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
Cancer epigenetics. CA Cancer J Clin (2010) 2.16
Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A (2004) 2.16
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A (2005) 2.16
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell (2009) 2.09
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol (2011) 2.07
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (2002) 2.04
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Telomere binding protein Taz1 establishes Swi6 heterochromatin independently of RNAi at telomeres. Curr Biol (2005) 2.02
Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res (2007) 2.02
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2004) 2.01
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis. J Biol Chem (2004) 1.97
Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet (2003) 1.93
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain (2010) 1.90
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev (2009) 1.88
CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol (2002) 1.83
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques (2007) 1.78
Neuron-specific relaxation of Igf2r imprinting is associated with neuron-specific histone modifications and lack of its antisense transcript Air. Hum Mol Genet (2005) 1.76
CIMP, at last. Gastroenterology (2005) 1.74
Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice. J Clin Invest (2014) 1.71
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood (2008) 1.71
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol Cell Biol (2005) 1.67
Splicing factors facilitate RNAi-directed silencing in fission yeast. Science (2008) 1.65
O-linked N-acetylglucosamine is present on the extracellular domain of notch receptors. J Biol Chem (2008) 1.65
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 1.65
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene (2004) 1.63
Characterization of microRNAs involved in embryonic stem cell states. Stem Cells Dev (2010) 1.62
Genistein alters methylation patterns in mice. J Nutr (2002) 1.60
Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer (2011) 1.60
Decitabine--bedside to bench. Crit Rev Oncol Hematol (2006) 1.59
Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A (2003) 1.57
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis (2008) 1.57
Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol (2002) 1.56
Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol (2007) 1.56
DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer (2010) 1.55
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res (2010) 1.53
Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res (2004) 1.52